Author:
Yu Yanke,DuBois Steven G.,Wetmore Cynthia,Khosravan Reza
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Pfizer Inc. Sutent (sunitinib malate) prescribing information. Pfizer Inc 2006 [last update: Nov 2017]. http://labeling.pfizer.com/showlabeling.aspx?id=607. Accessed 19 Jun 2019.
2. Bello C, Bu Hai-Shi, Patyna S, Kang P, Peng G, Pool W, et al. A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib(SU11248) in healthy male subjects [Abstract LB-354]. 2007 Annual Meeting of the American Association for Cancer Research (AACR); Los Angeles, CA; April 14-18, 2007.
3. Kloth JS, Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, et al. Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence. Clin Pharmacokinet. 2015;54:851–8. https://doi.org/10.1007/s40262-015-0239-5.
4. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study. Clin Cancer Res. 2011;17:5113–22. https://doi.org/10.1158/1078-0432.CCR-11-0237.
5. Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a Children’s Oncology Group Study ACNS1021. Cancer Med. 2016;5:1416–24. https://doi.org/10.1002/cam4.713.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献